Ruboxistaurin (Eli Lilly)

IDrugs. 2003 Feb;6(2):159-63.

Abstract

Eli Lilly & Co is developing the protein kinase C (PKC)-b inhibitor ruboxistaurin, the lead compound from a series of 14-membered macrocycles, for the potential treatment of diabetic retinopathy, diabetic peripheral neuropathy and macular edema.

Publication types

  • Review

MeSH terms

  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Diabetic Neuropathies / drug therapy
  • Diabetic Neuropathies / enzymology
  • Diabetic Retinopathy / drug therapy
  • Diabetic Retinopathy / enzymology
  • Enzyme Inhibitors* / chemistry
  • Enzyme Inhibitors* / pharmacology
  • Enzyme Inhibitors* / therapeutic use
  • Humans
  • Protein Kinase C / antagonists & inhibitors
  • Structure-Activity Relationship
  • Treatment Outcome

Substances

  • Enzyme Inhibitors
  • Protein Kinase C